CU20090161A7 - Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2 - Google Patents

Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2

Info

Publication number
CU20090161A7
CU20090161A7 CU20090161A CU20090161A CU20090161A7 CU 20090161 A7 CU20090161 A7 CU 20090161A7 CU 20090161 A CU20090161 A CU 20090161A CU 20090161 A CU20090161 A CU 20090161A CU 20090161 A7 CU20090161 A7 CU 20090161A7
Authority
CU
Cuba
Prior art keywords
piperazinas
pirimidinil
legands
receiver
useful
Prior art date
Application number
CU20090161A
Other languages
English (en)
Other versions
CU23853B1 (es
Inventor
Zsolt Komlodi
Eva Schmidt
Katalin Saghy
Judit Laszy
Bela Kiss
Istvan Gyertyan
Csongor Eva Againe
Szalai Gisella Bartane
Sandor Farkas
Gyoergy Domany
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CU20090161A7 publication Critical patent/CU20090161A7/es
Publication of CU23853B1 publication Critical patent/CU23853B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Abstract

La presente invención se relaciona con nuevos ligandos de dopamina D3 y D2 de fórmula (I): ESPACIO PARA LA FÓRMULA en donde R1, R2 y Q son como se describe aquí, y/o isómeros geométricos y/o estereoisómeros y/o diastereómeros y/o sales y/o hidratos y/o solvatos y/o polimorfos de los mismos. La invención también se relaciona con procesos para preparar los mismos, con composiciones que contienen los mismos y con su uso en el tratamiento y/o prevención de afecciones que requieren modulación de receptores de dopamina.
CU2009000161A 2007-04-11 2009-09-25 Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2 CU23853B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700269A HUP0700269A2 (en) 2007-04-11 2007-04-11 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
PCT/HU2008/000032 WO2008125891A2 (en) 2007-04-11 2008-04-10 Pyrimidinyl-piperazines useful as dopamine d3 /d2 receptor ligands

Publications (2)

Publication Number Publication Date
CU20090161A7 true CU20090161A7 (es) 2011-09-21
CU23853B1 CU23853B1 (es) 2012-10-15

Family

ID=38336883

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000161A CU23853B1 (es) 2007-04-11 2009-09-25 Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2

Country Status (36)

Country Link
EP (1) EP2132185B1 (es)
JP (1) JP4580464B2 (es)
KR (1) KR101540821B1 (es)
CN (1) CN101652351B (es)
AP (1) AP2460A (es)
AT (1) ATE518843T1 (es)
AU (1) AU2008237696B2 (es)
BR (1) BRPI0809641A2 (es)
CA (1) CA2682817C (es)
CO (1) CO6241116A2 (es)
CR (1) CR11071A (es)
CU (1) CU23853B1 (es)
CY (1) CY1111962T1 (es)
DK (1) DK2132185T3 (es)
EA (1) EA016174B1 (es)
EC (1) ECSP099702A (es)
ES (1) ES2370748T3 (es)
GE (1) GEP20115272B (es)
HK (1) HK1134491A1 (es)
HR (1) HRP20110785T8 (es)
HU (1) HUP0700269A2 (es)
IL (1) IL200801A0 (es)
MA (1) MA31359B1 (es)
MX (1) MX2009010896A (es)
MY (1) MY148384A (es)
NI (1) NI200900179A (es)
NZ (1) NZ579754A (es)
PL (1) PL2132185T3 (es)
PT (1) PT2132185E (es)
RS (1) RS51979B (es)
SI (1) SI2132185T1 (es)
TN (1) TN2009000386A1 (es)
TW (1) TWI445534B (es)
UA (1) UA103748C2 (es)
WO (1) WO2008125891A2 (es)
ZA (1) ZA200906543B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091489B2 (en) 2010-05-14 2015-07-28 Paragon Space Development Corporation Radiator systems
CN103052636B (zh) 2010-06-18 2016-03-09 阿尔托斯治疗有限责任公司 D2拮抗剂及其合成方法和使用方法
US9376396B2 (en) * 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
HU229987B1 (en) * 2012-11-21 2015-04-28 Richter Gedeon Nyrt Process for the preparation of pyrimidinyl-piperazines
WO2018021447A1 (ja) 2016-07-28 2018-02-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
JP7250405B2 (ja) * 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
WO2019146739A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する縮環化合物
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2311776A1 (fr) * 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands

Also Published As

Publication number Publication date
TN2009000386A1 (en) 2010-12-31
AU2008237696A1 (en) 2008-10-23
BRPI0809641A2 (pt) 2014-11-11
EP2132185B1 (en) 2011-08-03
WO2008125891A3 (en) 2009-01-08
JP2010523642A (ja) 2010-07-15
EP2132185A2 (en) 2009-12-16
ATE518843T1 (de) 2011-08-15
ES2370748T3 (es) 2011-12-22
HK1134491A1 (en) 2010-04-30
PL2132185T3 (pl) 2011-12-30
KR101540821B1 (ko) 2015-07-30
UA103748C2 (uk) 2013-11-25
ECSP099702A (es) 2009-11-30
MY148384A (en) 2013-04-15
NI200900179A (es) 2010-06-30
CA2682817C (en) 2015-11-24
AP2460A (en) 2012-09-13
CU23853B1 (es) 2012-10-15
CY1111962T1 (el) 2015-11-04
TW201002328A (en) 2010-01-16
CN101652351A (zh) 2010-02-17
EA016174B1 (ru) 2012-02-28
PT2132185E (pt) 2011-11-21
CA2682817A1 (en) 2008-10-23
KR20100082713A (ko) 2010-07-19
IL200801A0 (en) 2010-05-17
MA31359B1 (fr) 2010-05-03
DK2132185T3 (da) 2011-10-03
ZA200906543B (en) 2010-06-30
HU0700269D0 (en) 2007-05-29
HRP20110785T8 (en) 2012-04-30
SI2132185T1 (sl) 2011-11-30
NZ579754A (en) 2011-11-25
HUP0700269A2 (en) 2009-04-28
MX2009010896A (es) 2009-12-14
JP4580464B2 (ja) 2010-11-10
HRP20110785T1 (hr) 2011-11-30
GEP20115272B (en) 2011-08-25
AP2009004970A0 (en) 2009-10-31
CR11071A (es) 2009-11-20
EA200901391A1 (ru) 2010-02-26
WO2008125891A2 (en) 2008-10-23
TWI445534B (zh) 2014-07-21
AU2008237696B2 (en) 2013-03-14
CO6241116A2 (es) 2011-01-20
CN101652351B (zh) 2012-07-04
RS51979B (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CU23853B1 (es) Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2
UY36907A (es) Nuevas carboxamidas de acción microbiocida
PH12015501934B1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY32996A (es) Antagonistas del receptor crth2 basados en indol
ECSP14013264A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
ECSP11011206A (es) Nuevos herbicidas.
SV2010003687A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ECSP11011244A (es) Nuevos herbicidas.
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
NI200700319A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento.
ECSP11011218A (es) Herbicidas derivados de ciclopentanodiona.
ECSP11010786A (es) 5-alquinil-pirimidinas
ECSP11011133A (es) Nuevos herbicidas.
ECSP11011245A (es) Novedosos herbicidas
UY32667A (es) Nuevos derivados de furano espiroheterocíclico y tiofuranodiona
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP11011217A (es) Microbiocidas nuevos.
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
CL2011001850A1 (es) Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.
SV2011003821A (es) Compuestos de fenantrenona, composiciones y metodos
UY32772A (es) Etilamidas de benzotienilo novedosas y sus usos como microbicidas
CU20100249A7 (es) Derivados de benzoxazinona que actúan como agonistas de receptores adrenérgcos beta2 para el tratamiento de trastornos respiratorios
DOP2009000063A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contiene dichos compuestos y procedimientos

Legal Events

Date Code Title Description
FG Grant of patent